Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Mal de Melada (MdM) is a diffuse palmoplantar keratoderma initially reported from of the Island of Meleda characterized by symmetric palmoplantar hyperkeratosis that progressively extends to the dorsal surfaces of hands and feet (transgradiens). The disease can be associated to hyperhidrosis, lichenoid plaques and perioral erythema.
Features include: Perioral erythema, Fragile nails, Brachydactyly, and Dry, scaly skin (ichthyosis) and 2 more.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Skin | 5 | Perioral erythema, Fragile nails, Dry, scaly skin (ichthyosis) |
Pregnancy and birth |
SLURP1 function has not been fully characterized.
Mal de Meleda is associated with mutations in the SLURP1 gene on chromosome 8.
Genetic testing for SLURP1 is available. Testing is considered confirmatory for diagnosis.
Estimated prevalence: 1-9 in 100,000 (Uncommon).
No clinical trials have been registered for mal de Meleda.
10 publications have been identified in PubMed for mal de Meleda. Research spans Case Report / Case Series (50%), Other (20%), and Basic Science / Preclinical (20%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 5 | 50% |
Data assembled from 6 of 12 sources · Last updated Sep 17, 2026, 11:49 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
1 |
Congenital symmetrical palmoplantar keratosis |
2 |
20% |
Laboratory research | 2 | 20% |
Research summaries | 1 | 10% |
Kubo A (2025). [PMID: 39749860](https://pubmed.ncbi.nlm.nih.gov/39749860/). *J Dermatol*. [Review / Meta-Analysis]
Jiang X (2025). [PMID: 39913669](https://pubmed.ncbi.nlm.nih.gov/39913669/). *Br J Dermatol*. [Basic Science / Preclinical]
Onisor C (2025). [PMID: 41048964](https://pubmed.ncbi.nlm.nih.gov/41048964/). *Front Med (Lausanne)*. [Case Report / Case Series]
Takeichi T (2025). [PMID: 39953724](https://pubmed.ncbi.nlm.nih.gov/39953724/). *Br J Dermatol*. [Other]
Somasundaram A (2025). [PMID: 41296518](https://pubmed.ncbi.nlm.nih.gov/41296518/). *Indian J Dermatol Venereol Leprol*. [Other]
De Matos PR (2025). [PMID: 40110825](https://pubmed.ncbi.nlm.nih.gov/40110825/). *Eur J Dermatol*. [Case Report / Case Series]
Gong Z (2025). [PMID: 40023748](https://pubmed.ncbi.nlm.nih.gov/40023748/). *J Dermatol Sci*. [Case Report / Case Series]
Weinberg RL (2024). [PMID: 38866482](https://pubmed.ncbi.nlm.nih.gov/38866482/). *J Neurosci*. [Basic Science / Preclinical]
Khan A (2024). [PMID: 38903266](https://pubmed.ncbi.nlm.nih.gov/38903266/). *Cureus*. [Case Report / Case Series]
İmren IG (2024). [PMID: 38647179](https://pubmed.ncbi.nlm.nih.gov/38647179/). *Int J Dermatol*. [Case Report / Case Series]